Welcome to our dedicated page for Cbdmd SEC filings (Ticker: YCBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The cbdMD, Inc. (NYSE American: YCBD) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures from EDGAR with AI-supported summaries to help interpret key documents. cbdMD is a North Carolina corporation focused on hemp-derived cannabinoid products and related wellness brands, and its filings provide detailed insight into its operations, capital structure, and risk profile.
Investors can review annual reports on Form 10-K for discussions of cbdMD’s multi-brand business model spanning cbdMD, Paw CBD, ATRx Labs, and Herbal Oasis, along with risk factors, going concern language, and descriptions of its hemp-derived CBD and Delta-9 product lines. Quarterly reports on Form 10-Q offer interim financial statements and management discussion of sales trends, gross margins, and operating results.
cbdMD also files numerous current reports on Form 8-K that document material events. Recent 8-Ks describe preferred stock financings, the adoption of an equity compensation plan, regaining compliance with NYSE American listing standards, and the asset purchase of Gaia Botanicals, LLC, including the Bluebird Botanicals brand and online CBD marketplace. These filings outline terms of capital raises, equity designations, and key transaction details. Additional registration statements on Form S-1 and S-1/A cover resale registrations for shares issuable upon conversion of preferred stock and shares tied to an equity line of credit with an institutional investor.
On this page, AI-generated overviews can help explain complex sections of cbdMD’s 10-K and 10-Q filings, highlight significant items in 8-Ks, and summarize registration statements related to equity offerings. Users can also access information about equity compensation plans and preferred stock designations, and track any insider or significant shareholder activity reported in relevant forms. Combined, these SEC filings give a structured view of YCBD’s financial condition, financing arrangements, corporate governance, and strategic transactions, supporting deeper analysis of the company’s stock.
cbdMD, Inc. is registering up to 1,700,000 shares of common stock for potential resale by investors who purchased its Series B Convertible Preferred Stock in a prior private placement. The company will not receive any proceeds from these resales; it already raised $1,700,000 of gross proceeds when it issued 1,700,000 Series B shares on September 29, 2025 for working capital and general corporate purposes.
Each Series B share converts at $1.00 per share, subject to anti-dilution adjustments with a $0.50 floor, and pays a 10% annual dividend in stock or cash if certain equity conditions are met. As of December 19, 2025, cbdMD had 8,959,410 common shares outstanding, which would increase to 10,659,410 if all Series B shares convert at $1.00.
The preferred stock is senior to common in a liquidation and includes a 4.99% beneficial ownership cap per holder and a 19.99% NYSE American exchange cap (1,782,518 shares) unless shareholders approve a larger issuance. Management reports fiscal 2025 progress with GAAP operating loss reduced from $3.3 million to $2.1 million, while expanding its Oasis hemp-derived beverage brand amid increasing state and federal regulatory pressures on the hemp industry.
cbdMD, Inc. has filed a resale registration covering up to 1,700,000 shares of common stock issuable upon conversion of its Series B Convertible Preferred Stock. These shares may be sold from time to time by the selling shareholders, and cbdMD will not receive any proceeds from their resale, having previously raised $1.7 million in gross proceeds when it sold 1,700,000 Series B preferred shares in a private placement. The Series B Preferred Stock converts at $1.00 per share, subject to anti-dilution with a $0.50 floor, and carries a 10% annual dividend payable in stock or cash if certain conditions are met. As of December 19, 2025, cbdMD had 8,959,410 common shares outstanding, or 10,659,410 shares assuming full Series B conversion at $1.00 per share. The company’s stock trades on the NYSE American under the symbol YCBD, with a last reported price of $1.93 on December 18, 2025.
cbdMD, Inc. received an updated ownership report from investor Clark R. Crosnoe and related entities on a passive basis. Crosnoe is reported to beneficially own 436,150 common shares, representing 4.9% of the class, through CRC Investment Fund LP, NM 2018 Trust, and AMC Legacy Trust, all of which show shared voting and dispositive power and no sole power.
CRC Investment Fund LP reports beneficial ownership of 361,400 common shares, or 4.1% of the class. NM 2018 Trust reports 56,875 shares (about 0.6%), and AMC Legacy Trust reports 17,875 shares (about 0.2%). The percentages are calculated based on 8,919,410 common shares outstanding as of November 6, 2025, as disclosed in cbdMD’s Form S-1. Crosnoe disclaims beneficial ownership of securities held by the fund and trusts except to the extent of his pecuniary interest, and certifies that the holdings are not for the purpose of changing or influencing control of cbdMD.
cbdMD, Inc. is a North Carolina-based consumer wellness company that sells hemp-derived CBD, Delta‑9 THC where permitted, functional mushroom products, pet wellness items, and a new THC-infused beverage line under brands including cbdMD, Paw CBD, ATRX and Oasis. For fiscal 2025, revenue was essentially flat at $19.2 million, but the company narrowed its GAAP operating loss from $3.3 million in 2024 to $2.1 million in 2025 through cost controls and portfolio optimization.
Management simplified the capital structure by converting Series A preferred stock and accrued dividends into roughly 91% of the outstanding common shares following an April 2025 shareholder vote, which was critical to regaining compliance with NYSE American listing standards. However, the company still has a history of losses, faces liquidity pressure, and its auditors highlight substantial doubt about its ability to continue as a going concern without improved profitability or new funding.
Growth efforts include expanding Oasis hemp-derived THC beverages across the Southeast, strengthening e-commerce (about 77% of 2025 sales) and international distribution, and investing about $4.4 million in 2025 marketing. A major risk is regulatory: a new federal law could cap THC at 0.4 mg per container from November 2026, potentially affecting 40–45% of revenue tied to full-spectrum products, with future legislative fixes uncertain.
cbdMD, Inc. insider Clark R. Crosnoe, a director, reported multiple sales of the company’s common stock on 12/17/2025, all held indirectly through investment vehicles and trusts. These transactions are disclosed on a Form 4 filed for a single reporting person.
The filing shows a sale of 461,725 shares at $2.3136 per share through CRC Investment Fund LP, leaving 361,400 shares beneficially owned through that entity. It also reports a sale of 69,875 shares at $2.3444 per share through NM 2018 Trust, with 56,875 shares remaining, and a sale of 19,101 shares at $2.3444 per share through AMC Legacy Trust, with 17,875 shares remaining.
The reporting person states that beneficial ownership of these securities is disclaimed except to the extent of his pecuniary interest, so the reported indirect holdings reflect economic exposure rather than a claim to full ownership of all shares.
A stockholder in YCBD has filed a Rule 144 notice to sell up to 986,851 shares of common stock through Marex Capital Markets on the NYSE American, with an approximate sale date of 12/17/2025 and an aggregate market value of 2220415.00.
The securities were originally acquired on 12/09/2020 as an investment from the issuer and in the open market for cash, and the notice lists 8,912,959 shares of the issuer’s common stock outstanding as context for the planned sale. By signing, the seller represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.
cbdMD, Inc. reported that it has regained full compliance with the continued listing standards of the NYSE American exchange. NYSE Regulation sent the company a letter on December 5, 2025 confirming that previously identified deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide have been resolved. As a result, the “.BC” below-compliance indicator will be removed from cbdMD’s ticker and the company will be taken off the exchange’s list of noncompliant issuers, while remaining subject to normal ongoing listing monitoring.
cbdMD, Inc. reported an insider equity transaction for its CEO and CFO, who is also a director, on a Form 4. On 11/28/2025, the executive acquired 445,000 shares of common stock as restricted stock. After this grant, the executive beneficially owns 513,722 common shares in total.
The restricted shares were granted under cbdMD’s 2025 Equity Compensation Plan, and the filing notes that the vesting and issuance of these shares are subject to shareholder approval. The company also explains that the current beneficial ownership amount does not reconcile to the prior report because of a scrivener’s error.
cbdMD, Inc. reported a new executive employment agreement and a fresh equity compensation plan. The company entered into a three-year agreement with CEO and CFO T. Ronan Kennedy, providing a base salary of $340,000 and a restricted stock award covering 445,000 shares of common stock under the new 2025 Equity Compensation Plan. Vesting and issuance of these shares are subject to shareholder approval.
The board approved the 2025 Equity Compensation Plan, which reserves 891,316 shares of common stock for options, restricted stock, and other stock-based awards. The plan includes an “evergreen” feature that can automatically increase the share pool annually based on a percentage of shares outstanding, subject to caps. Awards may be granted to employees, officers, directors, and consultants and are administered by the board’s Compensation, Corporate Governance and Nominating Committee. Grants under the plan will not vest until shareholders approve it, and incentive stock option treatment depends on that approval.
cbdMD, Inc. filed a Form 8-K to report that on November 21, 2025 it issued a press release announcing preliminary net revenues for its fourth quarter and fiscal year ended September 30, 2025, along with certain other operating data for those periods. The press release is included as Exhibit 99.1.
The company states that this information is being furnished, not filed, under the securities laws, which means it is not subject to certain liability provisions and is not automatically incorporated into other cbdMD, Inc. filings.